Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania

About this trial

The research study is being conducted to better understand parts of the human brain called the cortex, basal ganglia, thalamus, and cerebellum in patients with movement disorders (such as Parkinson's disease, essential tremor, dystonia, or ataxia). These brain structures are involved in movement disorders. This study attempts to better understand the brain electrical activity associated with these disorders, both in patients with and without deep brain stimulation (DBS). Recordings are made from the scalp with a noninvasive electrode and/or through the DBS stimulator if the participant has a stimulator model that is able to sense brain activity. These recordings are analyzed along with measures of movement disorder symptoms to identify brain signal signatures of symptoms.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients 18 years of age and above

Parkinson's disease

Dystonia

Tremor, including essential tremor

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Prescribed Medications

    Other intervention

    participant's movement disorders medications, prescribed by their treating physician

  • Deep brain stimulation adjustment

    Other intervention

    Deep brain stimulator parameters may be adjusted within normal clinical limits

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: Participants without Deep Brain StimulatorsExperimental treatment 1 intervention
Group B: Participants with Deep Brain StimulatorsExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Neural signal biomarkers

Spatiotemporal patterns of brain neural activity (neural signal biomarkers / neurophysiologic signatures) associated with movement disorders symptoms.

Time frame
5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.